Literature DB >> 22293056

Diabetes mellitus in Greenland.

Michael Lynge Pedersen1.   

Abstract

Fifty years ago type 2 diabetes mellitus was very rare in Greenland. Recent epidemiological studies have found a high prevalence of diabetes among Greenlanders comparable to levels among Inuit populations in Canada and Alaska. In 2008 a national diabetes programme was implemented aiming to improve the care for patients with type 2 diabetes mellitus in Greenland based on a donation from Novo Nordisk A/S to the national health care service. A diabetes concept based on national guidelines, systematized recording in an electronically medical record and feedback to the clinics were used to improve the diabetes care. The overall aim of this thesis was to evaluate if implementation of a diabetes programme in Greenland would have a measurable effect on the quality in diabetes care including diagnostic activity and screening for diabetic complications. Two observational and cross sectional studies were performed in Greenland 2008 and 2010 before and after implementation of the diabetes programme. The medical records of patients with diabetes were reviewed. The prevalence was estimated using the whole adult population in Greenland as background population. The quality of the diabetes care was monitored by 12 health care indicators. The prevalence of diagnosed cases with type 2 diabetes mellitus among Greenlanders has increased over a period of two years. In the same period a significant increase in the quality of care in diabetes in Greenland has been documented concerning all process-of-care indicators. Significantly regional variation in the diabetes care was demonstrated in 2008. The quality in the diabetes care was best in clinics with a database. In 2010 a more homogenate quality among the clinics in the diabetes care was demonstrated. These effects could be a result of the diabetes programme implanted in between the two observations. In conclusion, improved quality in the diabetes care along with an increasing prevalence of diagnosed type 2 diabetes mellitus has been documented after implementation of a diabetes programme. It is strongly recommended to maintain focus on the quality on the diabetes care in order to benefit from the programme in a long-term perspective.

Entities:  

Mesh:

Year:  2012        PMID: 22293056

Source DB:  PubMed          Journal:  Dan Med J        ISSN: 2245-1919            Impact factor:   1.240


  6 in total

1.  Diabetes care in the dispersed population of Greenland. A new model based on continued monitoring, analysis and adjustment of initiatives taken.

Authors:  Michael Lynge Pedersen
Journal:  Int J Circumpolar Health       Date:  2019       Impact factor: 1.228

2.  Use of glycosylated haemoglobin as diagnostic tool in Greenland: prevalence of diagnosed diabetes mellitus.

Authors:  Line Damsgaard; Michael Lynge Pedersen
Journal:  Diabetol Metab Syndr       Date:  2013-10-09       Impact factor: 3.320

3.  High awareness of diabetes in the health care system in Greenland measured as a proportion of population tested with glycated haemoglobin within 2 years.

Authors:  Michael Lynge Pedersen
Journal:  Diabetol Metab Syndr       Date:  2017-05-03       Impact factor: 3.320

4.  Prevalence of patients treated with anti-diabetic medicine in Greenland and Denmark. A cross-sectional register study.

Authors:  Ida Meklenborg; Michael Lynge Pedersen; Eva Cecilie Bonefeld-Jørgensen
Journal:  Int J Circumpolar Health       Date:  2018-12       Impact factor: 1.228

5.  Gestational diabetes mellitus in Greenland: a national study of prevalence and testing efficacy.

Authors:  Michael Lynge Pedersen; Jesper Olesen; Marit Eika Jørgensen; Peter Damm
Journal:  Int J Circumpolar Health       Date:  2016-08-24       Impact factor: 1.228

6.  Periodontal status among patients with diabetes in Nuuk, Greenland.

Authors:  Amanda Lamer Schjetlein; Marit Eika Jørgensen; Torsten Lauritzen; Michael Lynge Pedersen
Journal:  Int J Circumpolar Health       Date:  2014-12-11       Impact factor: 1.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.